McKesson has been on a powerful multi year run, and that climb now raises a simple question for you as a shareholder or prospective buyer. Is the current share price adequately explained by the cash the business is expected to generate over time, or has sentiment moved ahead of the underlying stream of cash flows?
- Over the past 5 years the stock has returned about 399.8%, which puts a lot of accumulated optimism on the line if those gains are not backed up by durable cash generation.
- Recent positive commentary from high profile market voices and a higher analyst price target point to stronger growth expectations, which can support a richer view of McKesson's future cash flow profile and the timing of those inflows.
- Prefer to judge McKesson on earnings? See what McKesson's 25.7x P/E says about the price.
For investors, the debate is whether today's valuation of McKesson is fully supported by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.
To benchmark McKesson's cash flow story against other opportunities in the market, it can help to compare it with companies in the solid balance sheet and fundamentals stocks screener (25 results)
Is McKesson Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash McKesson can return to shareholders over time. Latest twelve month free cash flow sits around $6.0b, and analyst projections point to ongoing growth in annual cash generation over the coming decade rather than a shrinking stream.
Those rising cash flow estimates mean the DCF model places McKesson's estimated intrinsic value substantially above the current share price of $1,010.43. Jim Cramer recently highlighted McKesson as a healthcare winner and Leerink lifted its price target, which partly explains why the traded price has already moved higher. Even so, the cash flow outlook in this model still suggests further upside in the underlying value story. Find out what McKesson could be worth using our Discounted Cash Flow (DCF) estimate.
The McKesson Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the McKesson valuation puzzle leaves off by spelling out which specific assumptions about its future growth path, margin profile, and earnings power would need to hold for the stock to be worth materially more or materially less than today's price. They sit on the platform's Community page as structured thought experiments rather than price targets. Each scenario lays out its own fair value logic and the underlying inputs, so you can track how those expectations line up with actual reported results over time.
One of the top community narratives on McKesson: roughly fairly valued
"Expansion of technology driven access platforms such as RxTS and CoverMyMeds, including programs for GLP 1 therapies and broader affordability and access solutions…"
Discover why this Narrative puts McKesson at roughly fairly valued.
One more McKesson check before you stop at price
Cash flows tell you what the shares might be worth, but the real steering wheel sits with the executives and board, and how they are rewarded for their decisions. See who runs McKesson and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com